Catalyst

We are committed to improving the lives of patients with rare diseases.

[Catalyst @CatalystForRare]

Today, we’re shining a light on myasthenia gravis (MG). To help bring more attention to this rare disease, we’re inviting everyone to join the Myasthenia Gravis Association's call to "light the globe."

Wear teal, decorate your porch or home, or add a touch of teal anywhere that feels meaningful to you. Let teal be seen and spark conversation.

If you take part, snap a photo, share it, and tag them—we’d love to see how you’re helping raise awareness and stand with the MG community: https://t.co/Sq043g5bL7.

#MG #LightTheGlobe

[Catalyst @CatalystForRare]

June is Myasthenia Gravis (MG) Awareness Month, and @MyastheniaOrg (MGFA) is shining a light on this often‑overlooked autoimmune disease. Lambert-Eaton myasthenic syndrome (LEMS) can cause extreme fatigue and significant muscle weakness, and MG is often mistaken for it. Learning to recognize the symptoms can lead to earlier, more accurate diagnoses—and better support for those affected.

See how to get involved: https://t.co/F6WmEceZu1 #raredisease #LEMS #MG

[Catalyst @CatalystForRare]

Team Catalyst is at @ASCO, a conference centered around oncology. Come visit the Catalyst table to learn about the link between small cell lung cancer and Lambert-Eaton myasthenic syndrome (LEMS): https://t.co/Q7AHG5bRPM.

#ASCO26

[Catalyst @CatalystForRare]

Our Patient Services team always works to put compassion into action. They gathered together, not for a meeting or a training, but for something far more personal: crafting handmade bears for young patients at Nicklaus Children's Hospital.

Read more about their experience: https://t.co/P3HoCafecJ.

#patient

[Catalyst @CatalystForRare]

#HappyMemorialDay

[Catalyst @CatalystForRare]

Documenting your health journey can make a meaningful difference when seeking answers. Emily, a mom living with Lambert‑Eaton myasthenic syndrome (#LEMS), kept careful notes about her symptoms, doctor's visits, and tests. Her persistence and note-taking helped lead to an accurate diagnosis. Her story is a reminder: your voice matters, and advocating for yourself is always worthwhile: https://t.co/liyEm2AHzj.

#raredisease

[Catalyst @CatalystForRare]

We are live at CureDuchenne FUTURES!

Visit us at our booth to meet our Advocacy team and learn more about our efforts to support and empower the Duchenne muscular dystrophy (DMD) community. We’re looking forward to meaningful conversations with patients and families—hope to see you there!
-

¡Estamos en CureDuchenne FUTURES!

Visítanos en el puesto para conocer a nuestro equipo de defensa del paciente y aprender más sobre cómo apoyamos y empoderamos a la comunidad de distrofia muscular de Duchenne (DMD). Esperamos conectar con pacientes, familias y cuidadores. ¡Nos vemos allí!

#FUTURES2026 #DMD #Duchenne

[Catalyst @CatalystForRare]

During our Catalyst Advocacy Scholars Summit (CASS) from the University of @NotreDame, the students didn’t just study hard; they laughed, explored the city, and soaked in every moment. Even in the midst of fun, they stayed rooted in their mission, constantly striving to grow as patient advocates and discover how they can make an even greater impact: https://t.co/lIh0pWrX0a. #CASS2026

[Catalyst @CatalystForRare]

Rich, a former police dispatcher, shares his experience of being diagnosed with Lambert‑Eaton myasthenic syndrome (#LEMS), how the condition affected his daily life, and what it meant to finally receive treatment.

Listen to Rich’s story and learn more about LEMS: https://t.co/RATzDaLuou

[Catalyst @CatalystForRare]

At the @PedsEndoSociety meeting, our Catalyst team had the opportunity to share more about Duchenne muscular dystrophy (DMD)—a rare neuromuscular disease affecting primarily boys—and our commitment to supporting the DMD community. Learn more about how we’re working to make a difference: https://t.co/3AkVuHoBcs.

#PES2026 #pedsendo2026

[Catalyst @CatalystForRare]

"Momentum: Care in Motion" is the theme of the 51st annual Oncology Nursing Society conference on May 13-17th. Team Catalyst will be there, and we'd love for you to visit our table to uncover the link between small cell lung cancer (SCLC) and Lambert-Eaton myasthenic syndrome (LEMS). Cancer-Associated LEMS is the most common condition of its type in people with SCLC: https://t.co/ZyukV7dVlt.

#ONSCongress

[Catalyst @CatalystForRare]

We recently attended the 2026 @MyastheniaOrg's National Patient Conference and also introduced a new resource for the first time: a brochure featuring a word puzzle designed to reflect the many pieces that often need to come together to reach a Lambert-Eaton myasthenic syndrome (LEMS) diagnosis. Inside, readers can find information about anti‑VGCC antibody testing, as well as a suggested conversation guide to help discuss symptoms with a healthcare provider.

It was incredibly meaningful to share these materials in person, hear your feedback, and continue learning alongside this community. Learn more: https://t.co/MnMtTtRRRK

#Advocacy #MGFANationalPatientConference

[Catalyst @CatalystForRare]

Happy Mother’s Day to the moms and mother figures who show up with love in so many ways. Whether you’re caring for furry family members or little (and not-so-little) humans, your compassion and devotion don’t go unnoticed.

Wishing you a day that feels as special as the care you give all year long. #MothersDay

[Catalyst @CatalystForRare]

The @AANmember Annual Meeting brought together cross‑functional Catalyst teams to explore and discuss needs and advancements being developed to support the rare neuromuscular disease community. Learn more: https://t.co/EBwrLgdLBd

#raredisease #AANAM

[Catalyst @CatalystForRare]

We are excited to announce that we have entered into a merger agreement to be acquired by @AngeliniPharma. This agreement combines #AngeliniPharma's global reach & capabilities with our infrastructure, enabling us to accelerate our goal of bringing breakthrough therapies & world-class patient services to more people living with #rarediseases worldwide.
Learn more: https://t.co/v0qRwurvem
@AngeliniPhUS

[Catalyst @CatalystForRare]

We recently returned from the 2026 @MyastheniaOrg's National Patient Conference, where we had the opportunity to connect with dozens of individuals living with seronegative myasthenia gravis (MG), along with their care partners and families. We’re deeply grateful to everyone who stopped by our table and shared their experiences—from long diagnostic journeys and misdiagnoses to the ongoing uncertainty that can remain even after receiving a diagnosis. These firsthand stories directly shape the resources we create and reinforce why this work matters.

Learn more: https://t.co/MnMtTtRk2c

#Advocacy #MGFANationalPatientConference

[Catalyst @CatalystForRare]

In this episode of the LEMSaware podcast, we spoke with Peter to explore his Lambert-Eaton myasthenic syndrome (#LEMS) journey. Peter is a former special forces veteran and a family man, determined to prove that LEMS hasn't defined his limits.

Listen to more: https://t.co/fbcvIN6uHm

[Catalyst @CatalystForRare]

At BioFlorida’s 10th Annual Life Science Showcase, our President & CEO, Rich Daly, shared our perspective on the next phase of Florida’s life sciences ecosystem: continued capital investment, strong growth, and a growing diversity of companies across pharma, medtech, diagnostics, and more.

We’re proud of Catalyst’s role in South Florida’s life sciences community over the past 24 years and look ahead with excitement to what the future holds for our company, the ecosystem, and the patients we serve.

Read more: https://t.co/hDQtTCN1t8

[Catalyst @CatalystForRare]

Are you at the Pediatric Endocrine Society conference? Come visit Catalyst booth #512 to learn more about Duchenne muscular dystrophy (DMD), a rare neuromuscular disease affecting mostly boys, and what we're doing to help support the community: https://t.co/3AkVuHp920.

#PES2026

[Catalyst @CatalystForRare]

Catalyst Pharmaceuticals, Inc. will report its first-quarter financial results on May 11 and provide a business update. We will also host a conference call and webcast on May 12 at 8:30 a.m. ET.

Learn more: https://t.co/HcPEpbQatO